Skip to main content
Erschienen in: Der Pathologe 5/2014

01.09.2014 | Übersichten

Histologische Malignitätsgraduierung des Ovarialkarzinoms

Überblick und Empfehlung

verfasst von: Prof. Dr. S. Hauptmann, A. du Bois, I. Meinhold-Herlein, J. Pfisterer, S. Avril

Erschienen in: Die Pathologie | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Malignitätsgraduierung des Ovarialkarzinoms ist für die Therapieentscheidung wichtig und hat prognostische Bedeutung. Bisher ist jedoch kein einheitliches System zur Graduierung etabliert. Mehrere Gradingsysteme sind in Gebrauch, wie z. B. das FIGO-, WHO- und Silverberg-Grading, die nicht oder nur unzureichend übersetzbar sind. Darüber hinaus lassen sich die einzelnen Gradingsysteme unterschiedlich gut auf die verschiedenen histologischen Typen des Ovarialkarzinoms anwenden. Für die serösen Karzinome hat sich ein binäres System durchgesetzt, das die unterschiedliche Pathogenese von Low-grade- und High-grade-Karzinomen widerspiegelt. Einheitliche Richtlinien zur Graduierung des Ovarialkarzinoms sind notwendig und sollten sich an der prognostischen Aussagekraft orientieren. In dieser Arbeit werden die verschiedenen vorhandenen Gradingsysteme vorgestellt und in ihrem prognostischen Wert verglichen. Die Arbeit zeigt auf, dass die Graduierung der Ovarialkarzinome typspezifisch erfolgen sollte und gibt Empfehlungen zur Graduierung der einzelnen histologischen Typen.
Literatur
1.
Zurück zum Zitat Ayhan A, Kurman RJ, Yemelyanova A et al (2009) Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol 33:1220–1224PubMedCentralPubMedCrossRef Ayhan A, Kurman RJ, Yemelyanova A et al (2009) Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol 33:1220–1224PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Ayhan A, Mao TL, Seckin T et al (2012) Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 22:1310–1315PubMedCentralPubMedCrossRef Ayhan A, Mao TL, Seckin T et al (2012) Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 22:1310–1315PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Benda JA, Zaino R (1994) GOG pathology group manual. Gynecologic Oncology Group, Buffalo Benda JA, Zaino R (1994) GOG pathology group manual. Gynecologic Oncology Group, Buffalo
4.
Zurück zum Zitat Bodurka DC, Deavers MT, Tian C et al (2012) Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 118:3087–3094PubMedCrossRef Bodurka DC, Deavers MT, Tian C et al (2012) Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 118:3087–3094PubMedCrossRef
5.
Zurück zum Zitat Eichhorn JH, Young RH (2004) Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis. Am J Surg Pathol 28:453–463PubMedCrossRef Eichhorn JH, Young RH (2004) Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis. Am J Surg Pathol 28:453–463PubMedCrossRef
6.
Zurück zum Zitat Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef
7.
Zurück zum Zitat Espinosa I, Catasus L, Canet B et al (2011) Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol 24:846–854PubMedCrossRef Espinosa I, Catasus L, Canet B et al (2011) Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol 24:846–854PubMedCrossRef
8.
Zurück zum Zitat Farley JFPi, DiSaia PJGOG (2011) A phase II evaluation of temsirolimus (CCI-779) in combination with carboplatin and paclitaxel followed by temsirolimus (CCI-779) consolidation as first-line therapy in the treatment of stage III-IV clear cell carcinoma of the ovary In: ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT01196429) Farley JFPi, DiSaia PJGOG (2011) A phase II evaluation of temsirolimus (CCI-779) in combination with carboplatin and paclitaxel followed by temsirolimus (CCI-779) consolidation as first-line therapy in the treatment of stage III-IV clear cell carcinoma of the ovary In: ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT01196429)
9.
Zurück zum Zitat Gore ME, Gershenson DMPiUCL (2012) Carboplatin and paclitaxel or oxaliplatin and capecitabine, with or without bevacizumab, as first-line therapy in treating patients with newly diagnosed stage II, stage III, stage IV, or recurrent stage I epithelial ovarian cancer or fallopian tube cancer. In: ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT01081262) Gore ME, Gershenson DMPiUCL (2012) Carboplatin and paclitaxel or oxaliplatin and capecitabine, with or without bevacizumab, as first-line therapy in treating patients with newly diagnosed stage II, stage III, stage IV, or recurrent stage I epithelial ovarian cancer or fallopian tube cancer. In: ClinicalTrials.gov (ClinicalTrials.gov Identifier: NCT01081262)
10.
Zurück zum Zitat Hart WR, Norris HJ (1973) Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 31:1031–1045PubMedCrossRef Hart WR, Norris HJ (1973) Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 31:1031–1045PubMedCrossRef
11.
Zurück zum Zitat Hoerl HD, Hart WR (1998) Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 22:1449–1462PubMedCrossRef Hoerl HD, Hart WR (1998) Primary ovarian mucinous cystadenocarcinomas: a clinicopathologic study of 49 cases with long-term follow-up. Am J Surg Pathol 22:1449–1462PubMedCrossRef
12.
Zurück zum Zitat Kommoss F, Kommoss S, Schmidt D et al (2005) Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol 97:195–199PubMedCrossRef Kommoss F, Kommoss S, Schmidt D et al (2005) Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol 97:195–199PubMedCrossRef
13.
Zurück zum Zitat Kommoss S, Bois A du, Schmidt D et al (2006) Chemotherapy may be more effective in highly proliferative ovarian carcinomas – a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Gynecol Oncol 103:67–71PubMedCrossRef Kommoss S, Bois A du, Schmidt D et al (2006) Chemotherapy may be more effective in highly proliferative ovarian carcinomas – a translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Gynecol Oncol 103:67–71PubMedCrossRef
14.
Zurück zum Zitat Kommoss S, Schmidt D, Kommoss F et al (2009) Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Virchows Arch 454:249–256PubMedCrossRef Kommoss S, Schmidt D, Kommoss F et al (2009) Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol). Virchows Arch 454:249–256PubMedCrossRef
15.
16.
Zurück zum Zitat Kurman RJ, Carcangiu LM, Herrington CS, Young RH (eds) (2014) WHO classification of tumours of female reproductive organs. IARC Press, Lyon Kurman RJ, Carcangiu LM, Herrington CS, Young RH (eds) (2014) WHO classification of tumours of female reproductive organs. IARC Press, Lyon
17.
Zurück zum Zitat Lee KR, Scully RE (2000) Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‚pseudomyxoma peritonei’. Am J Surg Pathol 24:1447–1464PubMedCrossRef Lee KR, Scully RE (2000) Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‚pseudomyxoma peritonei’. Am J Surg Pathol 24:1447–1464PubMedCrossRef
18.
Zurück zum Zitat Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2013) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Version 1.0. AWMF Registrierungsnummer: 032-035OL. http://leitlinienprogramm-onkologiede/Leitlinien70html Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2013) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Version 1.0. AWMF Registrierungsnummer: 032-035OL. http://​leitlinienprogra​mm-onkologiede/​Leitlinien70html​
19.
Zurück zum Zitat Mackay HJ, Brady MF, Oza AM et al (2010) Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 20:945–952PubMedCrossRef Mackay HJ, Brady MF, Oza AM et al (2010) Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 20:945–952PubMedCrossRef
20.
Zurück zum Zitat Malpica A (2008) Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol 27:175–181PubMed Malpica A (2008) Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol 27:175–181PubMed
21.
Zurück zum Zitat Malpica A, Deavers MT, Lu K et al (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496–504PubMedCrossRef Malpica A, Deavers MT, Lu K et al (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28:496–504PubMedCrossRef
22.
Zurück zum Zitat Malpica A, Deavers MT, Tornos C et al (2007) Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1168–1174PubMedCrossRef Malpica A, Deavers MT, Tornos C et al (2007) Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol 31:1168–1174PubMedCrossRef
23.
Zurück zum Zitat McCluggage WG (2011) Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43:420–432PubMedCrossRef McCluggage WG (2011) Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43:420–432PubMedCrossRef
24.
Zurück zum Zitat Riopel MA, Ronnett BM, Kurman RJ (1999) Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 23:617–635PubMedCrossRef Riopel MA, Ronnett BM, Kurman RJ (1999) Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 23:617–635PubMedCrossRef
25.
Zurück zum Zitat Ryu SY, Park SI, Nam BH et al (2009) Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group. Ann Oncol 20:1032–1036PubMedCrossRef Ryu SY, Park SI, Nam BH et al (2009) Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group. Ann Oncol 20:1032–1036PubMedCrossRef
26.
Zurück zum Zitat Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511–1518PubMedCentralPubMedCrossRef Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511–1518PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Shimizu Y, Kamoi S, Amada S et al (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82:893–901PubMedCrossRef Shimizu Y, Kamoi S, Amada S et al (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82:893–901PubMedCrossRef
28.
Zurück zum Zitat Shimizu Y, Kamoi S, Amada S et al (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features – problems involved in the architectural grading system. Gynecol Oncol 70:2–12PubMedCrossRef Shimizu Y, Kamoi S, Amada S et al (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features – problems involved in the architectural grading system. Gynecol Oncol 70:2–12PubMedCrossRef
29.
Zurück zum Zitat Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7–15PubMedCrossRef Silverberg SG (2000) Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 19:7–15PubMedCrossRef
30.
Zurück zum Zitat Singer G, Oldt R, III, Cohen Y et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484–486PubMedCrossRef Singer G, Oldt R, III, Cohen Y et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484–486PubMedCrossRef
31.
Zurück zum Zitat Singh N, Ayhan A, Menon U et al (2008) Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems. Histopathology 52:393–395PubMedCrossRef Singh N, Ayhan A, Menon U et al (2008) Grading of serous ovarian carcinoma: further evidence of a lack of agreement between conventional grading systems. Histopathology 52:393–395PubMedCrossRef
32.
Zurück zum Zitat Uzan C, Berretta R, Rolla M et al (2012) Management and prognosis of endometrioid borderline tumors of the ovary. Surg Oncol 21:178–184PubMedCrossRef Uzan C, Berretta R, Rolla M et al (2012) Management and prognosis of endometrioid borderline tumors of the ovary. Surg Oncol 21:178–184PubMedCrossRef
33.
Zurück zum Zitat Vang R, Shih Ie M, Salani R et al (2008) Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol 32:1667–1674PubMedCrossRef Vang R, Shih Ie M, Salani R et al (2008) Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol 32:1667–1674PubMedCrossRef
34.
Zurück zum Zitat Watkin W, Silva EG, Gershenson DM (1992) Mucinous carcinoma of the ovary. Pathologic prognostic factors. Cancer 69:208–212PubMedCrossRef Watkin W, Silva EG, Gershenson DM (1992) Mucinous carcinoma of the ovary. Pathologic prognostic factors. Cancer 69:208–212PubMedCrossRef
35.
Zurück zum Zitat Yamamoto S, Kasajima A, Takano M et al (2011) Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group. Int J Gynecol Pathol 30:129–138PubMedCrossRef Yamamoto S, Kasajima A, Takano M et al (2011) Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group. Int J Gynecol Pathol 30:129–138PubMedCrossRef
36.
Zurück zum Zitat Yamamoto S, Tsuda H, Takano M et al (2012) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 25:615–624PubMedCrossRef Yamamoto S, Tsuda H, Takano M et al (2012) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 25:615–624PubMedCrossRef
37.
Zurück zum Zitat Young RH, Hart WR (1992) Renal cell carcinoma metastatic to the ovary: a report of three cases emphasizing possible confusion with ovarian clear cell adenocarcinoma. Int J Gynecol Pathol 11:96–104PubMedCrossRef Young RH, Hart WR (1992) Renal cell carcinoma metastatic to the ovary: a report of three cases emphasizing possible confusion with ovarian clear cell adenocarcinoma. Int J Gynecol Pathol 11:96–104PubMedCrossRef
38.
Zurück zum Zitat Young RH, Scully RE (1987) Oxyphilic clear cell carcinoma of the ovary. A report of nine cases. Am J Surg Pathol 11:661–667PubMedCrossRef Young RH, Scully RE (1987) Oxyphilic clear cell carcinoma of the ovary. A report of nine cases. Am J Surg Pathol 11:661–667PubMedCrossRef
39.
Zurück zum Zitat Zaino RJ, Kurman RJ, Diana KL, Morrow CP (1995) The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 75:81–86PubMedCrossRef Zaino RJ, Kurman RJ, Diana KL, Morrow CP (1995) The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 75:81–86PubMedCrossRef
Metadaten
Titel
Histologische Malignitätsgraduierung des Ovarialkarzinoms
Überblick und Empfehlung
verfasst von
Prof. Dr. S. Hauptmann
A. du Bois
I. Meinhold-Herlein
J. Pfisterer
S. Avril
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Pathologie / Ausgabe 5/2014
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI
https://doi.org/10.1007/s00292-014-1948-5

Weitere Artikel der Ausgabe 5/2014

Der Pathologe 5/2014 Zur Ausgabe

Einführung zum Thema

Hautadnextumoren

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.